Nanocarrier System: State-of-the-Art in Oral Delivery of Astaxanthin

Wahab, Nur Rafiqah Abdol; Affandi, Meor Mohd Redzuan Meor Mohd; Fakurazi, Sharida; Alias, Ekram; Hassan, Haniza

doi:10.3390/antiox11091676

Cited by 20 publications

(8 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ASX nanoparticles have good entrapment efficiency and high stability, but showed poor water solubilities and low loading rate of ASX. Compared with nanoparticles, nanoliposomes have less crystal arrangement in structure and can provide more ASX binding space ( Abdol Wahab et al, 2022 ). But the poor stability and inefficient encapsulation of nanoliposomes together with excessive lipid may cause more serious health problems for obese and hyperlipidemic population ( Sun et al, 2021 ).…”

Section: Limitations Of Current Application and Future Development Tr...mentioning

confidence: 99%

Research progress of Astaxanthin nano-based drug delivery system: Applications, prospects and challenges?

et al. 2023

View full text Add to dashboard Cite

Astaxanthin (ASX) is a kind of carotenoid widely distributed in nature, which has been shown to extremely strong antioxidative effects and significant preventive and therapeutic effects on cancer, diabetes, cardiovascular disease, etc. However, its application in the medical field is greatly limited due to its poor water solubility, unstable chemical properties and other shortcomings. In recent years, the nano-based drug delivery systems such as nanoparticles, liposomes, nanoemulsions, nanodispersions, and polymer micelles, have been used as Astaxanthin delivery carriers with great potential for clinical applications, which have been proved that they can enhance the stability and efficacy of Astaxanthin and achieve targeted delivery of Astaxanthin. Herein, based on the pharmacological effects of Astaxanthin, we reviewed the characteristics of various drug delivery carriers, which is of great significance for improving the bioavailability of Astaxanthin.

show abstract

Section: Limitations Of Current Application and Future Development Tr...mentioning

confidence: 99%

Research progress of Astaxanthin nano-based drug delivery system: Applications, prospects and challenges?

et al. 2023

View full text Add to dashboard Cite

show abstract

“…2017/2470. Abdol Wahab and co-workers recently reported the state of the art in the oral delivery of this carotenoid [81]. Bovine lactoferrin is a protein that naturally occurs in cow's milk with numerous beneficial activities, such as antimicrobial, anti-cancer, and anti-inflammatory effects [82].…”

Section: Compound Derived From Novel Foods Embedded Into Nanocarriersmentioning

confidence: 99%

Combination of Nanodelivery Systems and Constituents Derived from Novel Foods: A Comprehensive Review

Truzzi,

Bertelli,

Bilia

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Novel Food is a new category of food, regulated by the European Union Directive No. 2015/2283. This latter norm defines a food as “Novel” if it was not used “for human consumption to a significant degree within the Union before the date of entry into force of that regulation, namely 15 May 1997”. Recently, Novel Foods have received increased interest from researchers worldwide. In this sense, the key areas of interest are the discovery of new benefits for human health and the exploitation of these novel sources of materials in new fields of application. An emerging area in the pharmaceutical and medicinal fields is nanotechnology, which deals with the development of new delivery systems at a nanometric scale. In this context, this review aims to summarize the recent advances on the design and characterization of nanodelivery systems based on materials belonging to the Novel Food list, as well as on nanoceutical products formulated for delivering compounds derived from Novel Foods. Additionally, the safety hazard of using nanoparticles in food products, i.e., food supplements, has been discussed in view of the current European regulation, which considers nanomaterials as Novel Foods.

show abstract

“…The maximum plasma concentration and peak plasma concentration were 1.3 ± 0.1 mg/L and 6.7 ± 1.2 h, respectively. Similarly, the volume of distribution and oral clearance were 2.0 ± 1.3 L/kg and 3.3 ± 1.1 L/hour, respectively [ 17 ]. AST is safe at a dose of 4–18 mg daily for 12 weeks.…”

Section: Introductionmentioning

confidence: 99%

Astaxanthin: A Marine Drug That Ameliorates Cerebrovascular-Damage-Associated Alzheimer’s Disease in a Zebrafish Model via the Inhibition of Matrix Metalloprotease-13

Paramakrishnan,

Lim,

Paramaswaran

et al. 2023

Marine Drugs

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a major type of dementia disorder. Common cognitive changes occur as a result of cerebrovascular damage (CVD) via the disruption of matrix metalloproteinase-13 (MMP-13). In diabetic cases, the progress of vascular dementia is faster and the AD rate is higher. Patients with type 2 diabetes are known to have a higher risk of the factor for AD progression. Hence, this study is designed to investigate the role of astaxanthin (AST) in CVD-associated AD in zebrafish via the inhibition of MMP-13 activity. CVD was developed through the intraperitoneal and intracerebral injection of streptozotocin (STZ). The AST (10 and 20 mg/L), donepezil (1 mg/L), and MMP-13 inhibitor (i.e., CL-82198; 10 μM) were exposed for 21 consecutive days in CVD animals. The cognitive changes in zebrafish were evaluated through light and dark chamber tests, a color recognition test, and a T-maze test. The biomarkers of AD pathology were assessed via the estimation of the cerebral extravasation of Evans blue, tissue nitrite, amyloid beta-peptide aggregation, MMP-13 activity, and acetylcholinesterase activity. The results revealed that exposure to AST leads to ameliorative behavioral and biochemical changes. Hence, AST can be used for the management of AD due to its multi-targeted actions, including MMP-13 inhibition.

show abstract

Nanocarrier System: State-of-the-Art in Oral Delivery of Astaxanthin

Cited by 20 publications

References 73 publications

Research progress of Astaxanthin nano-based drug delivery system: Applications, prospects and challenges?

Research progress of Astaxanthin nano-based drug delivery system: Applications, prospects and challenges?

Combination of Nanodelivery Systems and Constituents Derived from Novel Foods: A Comprehensive Review

Astaxanthin: A Marine Drug That Ameliorates Cerebrovascular-Damage-Associated Alzheimer’s Disease in a Zebrafish Model via the Inhibition of Matrix Metalloprotease-13

Contact Info

Product

Resources

About